ACE inhibitor-induced angioedema: More common than previously thought

[1] Vleeming W., Van Amsterdam J.G.C., Stricker B.H.Ch., Et al., ACE inhibitor-induced angioedema. Incidence, prevention and management, Drug Saf, 18, 3, pp. 171-188, (1998)

[2] British National Formulary No. 35, 35, pp. 140-147, (1998)

[3] Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial, Arch Intern Med, 144, pp. 1947-1953, (1984)

[4] Williams G.H., Quality of life and its impact on hypertensive patients, Am J Med, 82, pp. 98-105, (1987)

[5] Cooper W.D., Sheldon D., Brown D., Et al., Post-marketing surveillance of enalapril: Experience in 11,710 hypertensive patients in general practice, J R Coll Gen Pract, 37, pp. 346-349, (1987)

[6] Inman W.H., Rawson N.S., Wilton L.V., Et al., Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring, BMJ, 297, pp. 826-829, (1988)

[7] Wood S.M., Mann R.D., Rawlins M.D., Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors, Br Med J Clin Res, 294, pp. 91-92, (1987)

[8] Israili Z.H., Hall W.D., Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiolosy, Ann Intern Med, 117, pp. 234-242, (1992)

[9] Dyer P.D., Late-onset angioedema after interruption of angiotensin converting enzyme inhibitor therapy, J Allergy Clin Immunol, 93, 5, pp. 947-948, (1994)

[10] Nielsen E.W., Stenberg P.A., Einarsen E., Et al., Angioedema associated with ACE inhibitors, Tidsskr Nor Laegeforen, 114, pp. 804-806, (1994)

[1] Vleeming W., Van Amsterdam J.G.C., Stricker B.H.Ch., Et al., ACE inhibitor-induced angioedema. Incidence, prevention and management, Drug Saf, 18, 3, pp. 171-188, (1998)

[2] British National Formulary No. 35, 35, pp. 140-147, (1998)

[3] Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial, Arch Intern Med, 144, pp. 1947-1953, (1984)

[4] Williams G.H., Quality of life and its impact on hypertensive patients, Am J Med, 82, pp. 98-105, (1987)

[5] Cooper W.D., Sheldon D., Brown D., Et al., Post-marketing surveillance of enalapril: Experience in 11,710 hypertensive patients in general practice, J R Coll Gen Pract, 37, pp. 346-349, (1987)

[6] Inman W.H., Rawson N.S., Wilton L.V., Et al., Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring, BMJ, 297, pp. 826-829, (1988)

[7] Wood S.M., Mann R.D., Rawlins M.D., Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors, Br Med J Clin Res, 294, pp. 91-92, (1987)

[8] Israili Z.H., Hall W.D., Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiolosy, Ann Intern Med, 117, pp. 234-242, (1992)

[9] Dyer P.D., Late-onset angioedema after interruption of angiotensin converting enzyme inhibitor therapy, J Allergy Clin Immunol, 93, 5, pp. 947-948, (1994)

[10] Nielsen E.W., Stenberg P.A., Einarsen E., Et al., Angioedema associated with ACE inhibitors, Tidsskr Nor Laegeforen, 114, pp. 804-806, (1994)